Triantafyllos Didangelos* and Konstantinos Kantartzis Pages 1 - 10 ( 10 )
The cardiac effects of exogenously administered insulin for the treatment of diabetes (DM) have recently attracted much attention. In particular, it has been questioned whether insulin is the appropriate treatment for patients with type 2 diabetes mellitus (T2DM) and heart failure. While several old and some new studies suggested that insulin treatment has beneficial effects for the heart, recent observational studies indicate associations of insulin treatment with increased risk of developing or worsening of a pre-existing heart failure and higher mortality rates. However, there is actually little evidence that the associations of insulin administration with any adverse outcomes are causal. On the other hand, insulin clearly causes weight gain and may also cause serious episodes of hypoglycemia. Moreover, hyperglycemia, as often seen with the use of injected insulin, seems to predispose to inflammation, hypertension, dyslipidemia, atherosclerosis, heart failure, and arrhythmias. Nevertheless, it should be stressed that most of the data concerning the effects of insulin on cardiac function derive from in vitro studies with isolated animal hearts. Therefore, the relevance of the findings of such studies for humans should be considered with caution. In the present review, we summarize existing data about the potential positive and negative effects of insulin on the heart and attempt to answer the question whether any adverse effects of insulin or the consequences of hyperglycemia are more important and may provide a better explanation of the close association of DM with heart failure.
Diabetes, insulin, heart failure, diastolic dysfunction, systolic dysfunction, cardiomyopathy, autonomic neuropathy.
Diabetes Center, 1st Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, ‘’AHEPA’’ Hospital, Thessaloniki, Department of Internal Medicine IV, Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, University of Tübingen and Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen